Regularly monitoring blood pressure is key to good health. But “garbage in = garbage out” as-always applies when it comes to ...

Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.